2015 Fiscal Year Final Research Report
Combination therapy using cancer vaccine, antigen-specific CTL and an anticancer drug for renal cell carcinoma
Project/Area Number |
24592415
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Aichi Medical University |
Principal Investigator |
|
Research Collaborator |
SUZUKI Susumu
KASHIWAGI Takahiro
NISHIO Mayako
NISHINO Tokiko
|
Project Period (FY) |
2012-04-01 – 2016-03-31
|
Keywords | 免疫治療 / 細胞治療 / 併用療法 / 抗がん剤 / CTL |
Outline of Final Research Achievements |
In this study, we tried to improve immune-cell therapy for cancer by improvement of an amplification system of cytotoxic T-cells (CTL) activated with cancer peptide vaccine and, combination with CTL and anticancer drugs. CTLs were able to induce and expand in efficiently using cancer peptide vaccine as activation antigen. The influence of anticancer drugs for CTLs were tested using CTLs activated with a CMV peptide. Docetaxel, Gemcitabin and Cisplatin did not show any influence for reactivity of CTL, but showed inhibition activity for proliferation. These results showed that Docetaxel, Gemcitabin and Cisplatin were able to use with CTLs for treatment with cancer patients, but not combination with peptide vaccines. Iressa, Sorafenib and 5-FU did not show any influence for reactive activity and proliferation of CTL, and direct cytotoxicity for CTLs. These results indicate that these drugs can be used with CTLs and peptide vaccines for the treatment of cancer patients.
|
Free Research Field |
腫瘍免疫学
|